Evidence map›Paper›PMID 24741098›Full record

ArticleJournal of virology2014

Vaccination with Gag, Vif, and Nef gene fragments affords partial control of viral replication after mucosal challenge with SIVmac239.

Mauricio A Martins, Nancy A Wilson, Shari M Piaskowski, Kim L Weisgrau, Jessica R Furlott, Myrna C Bonaldo, Marlon G Veloso de Santana, Richard A Rudersdorf, Eva G Rakasz, Karen D Keating and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. RecombinantVaccines · 2025
    Review
  3. Review
  4. Article
  5. Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Article
  6. Review
  7. Review
  8. Article
  9. Rhesus Cytomegalovirus-Specific CD8Frontiers in immunology · 2020
    Article
  10. Vaccine strategies for theNPJ vaccines · 2020
    Review
  11. Article
  12. Journal of virology · 2018
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 2 countries.

Mauricio A MartinsDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Nancy A WilsonDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Shari M PiaskowskiWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Kim L WeisgrauWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Jessica R FurlottWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Myrna C BonaldoLaboratório de Biologia Molecular de Flavivírus, Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.
Marlon G Veloso de SantanaDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Richard A RudersdorfWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Eva G RakaszWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Karen D KeatingSection on Statistical Genetics, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Maria J ChiuchioloInternational AIDS Vaccine Initiative, AIDS Vaccine Design and Development Laboratory, Brooklyn Army Terminal, Brooklyn, New York, USA.
Michael PiatakAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA.
David B AllisonSection on Statistical Genetics, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Christopher L ParksInternational AIDS Vaccine Initiative, AIDS Vaccine Design and Development Laboratory, Brooklyn Army Terminal, Brooklyn, New York, USA.
Ricardo GallerInstituto de Tecnologia em Imunobiológicos, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA.
David I WatkinsDepartment of Pathology, University of Miami Miller School of Medicine, Miami, Florida, USA dwatkins@med.miami.edu.
University of Wisconsin–Madison · USUniversity of Miami · USFundação Oswaldo Cruz · BRInternational AIDS Vaccine Initiative · USUniversity of Alabama at Birmingham · USLeidos Biomedical Research Inc. (United States)Leidos (United States) · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
ZOLEDRONATE PREVENTS BONE LOSS IN OVARIECTOMIZED RHESUS MONKEYSP51RR000167 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 1985 to 2011
$106.7M
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENTR01AI049120 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 2001 to 2009
$7.6M
EXTRAMURAL RES FACIL CONST: REPRODUCTIVE, GROWTH &DVMT, MENOPAUSEC06RR020141 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2004 to 2004
$3.6M
Minigene Vaccination with Early Presented Viral ProteinsR01AI076114 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI RAKASZ, EVA GIZELLA · 2007 to 2011
$3.3M
EXTRAMURAL REGIONAL FACILITIES CONSTRUCTIONC06RR015459 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2000 to 2000
$1.9M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCRR NIH HHS C06 RR015459NCRR NIH HHS C06 RR020141NCRR NIH HHS P51 RR000167NIAID NIH HHS R01 AI049120NIAID NIH HHS R01 AI076114NIH HHS P51 OD011106
6 · The paper itself

Abstract

unlabelledBroadly targeted cellular immune responses are thought to be important for controlling replication of human and simian immunodeficiency viruses (HIV and SIV). However, eliciting such responses by vaccination is complicated by immunodominance, the preferential targeting of only a few of the many possible epitopes of a given antigen. This phenomenon may be due to the coexpression of dominant and subdominant epitopes by the same antigen-presenting cell and may be overcome by distributing these sequences among several different vaccine constructs. Accordingly, we tested whether vaccinating rhesus macaques with "minigenes" encoding fragments of Gag, Vif, and Nef resulted in broadened cellular responses capable of controlling SIV replication. We delivered these minigenes through combinations of recombinant Mycobacterium bovis BCG (rBCG), electroporated recombinant DNA (rDNA) along with an interleukin-12 (IL-12)-expressing plasmid (EP rDNA plus pIL-12), yellow fever vaccine virus 17D (rYF17D), and recombinant adenovirus serotype 5 (rAd5). Although priming with EP rDNA plus pIL-12 increased the breadth of vaccine-induced T-cell responses, this effect was likely due to the improved antigen delivery afforded by electroporation rather than modulation of immunodominance. Indeed, Mamu-A*01(+) vaccinees mounted CD8(+) T cells directed against only one subdominant epitope, regardless of the vaccination regimen. After challenge with SIVmac239, vaccine efficacy was limited to a modest reduction in set point in some of the groups and did not correlate with standard T-cell measurements. These findings suggest that broad T-cell responses elicited by conventional vectors may not be sufficient to substantially contain AIDS virus replication. IMPORTANCE: Immunodominance poses a major obstacle to the generation of broadly targeted, HIV-specific cellular responses by vaccination. Here we attempted to circumvent this phenomenon and thereby broaden the repertoire of SIV-specific cellular responses by vaccinating rhesus macaques with minigenes encoding fragments of Gag, Vif, and Nef. In contrast to previous mouse studies, this strategy appeared to minimally affect monkey CD8(+) T-cell immundominance hierarchies, as seen by the detection of only one subdominant epitope in Mamu-A*01(+) vaccinees. This finding underscores the difficulty of inducing subdominant CD8(+) T cells by vaccination and demonstrates that strategies other than gene fragmentation may be required to significantly alter immunodominance in primates. Although some of the regimens tested here were extremely immunogenic, vaccine efficacy was limited to a modest reduction in set point viremia after challenge with SIVmac239. No correlates of protection were identified. These results reinforce the notion that vaccine immunogenicity does not predict control of AIDS virus replication.

Indexed as

Virus ReplicationAnimalsEnzyme-Linked Immunosorbent AssayFemaleGene Products, gagGene Products, nefGene Products, vifGenetic VectorsHistocompatibility Antigens Class IHumansImmunity, CellularMacaca mulattaMaleMiceSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusGene Products, gagGene Products, nefGene Products, vifHistocompatibility Antigens Class IMamu-B 01 antigen, Macaca mulattaVaccines, Synthetic

Identifiers

PMID24741098
PMCPMC4054456
OpenAlexW2043458308

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.